Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 424-435

  Thompson, Matthew D ^a   Beard, Daniel A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Asymptotic matching; Flow limited; compartmental modeling; In silico modeling; Pharmacokinetics; Physicochemical; Physiological model; Singular perturbation; Tissue partition; Well stirred model

Indexed keywords

ANIMAL TISSUE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG EXPOSURE; FLOW LIMITED TWO REGION ASYMPTOTICALLY REDUCED PHYSIOLOGICALLY BASED PHARMACOKINETIC TISSUE COMPARTMENT MODEL; NONHUMAN; PROCESS OPTIMIZATION; RAT; RISK ASSESSMENT; SIMULATION; WELL STIRRED TANK FLOW LIMITED PHYSIOLOGICALLY BASED PHARMACOKINETIC TISSUE COMPARTMENT MODEL;

EID: 82255192501     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22768     Document Type: Article

References (41)

1. Theil FP, Guentert TW, Haddad S, Poulin P. 2003. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29-49.
2. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Gil Berglund E, Lesko LJ, Huang SM. 2011. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259-267.
3. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
4. Andersen ME, Clewell H 3rd, Krishnan K. 1995. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Risk Anal 15:533-537.
5. Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 12:1-24.
6. Yang F, Tong X, McCarver DG, Hines RN, Beard DA. 2006. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 33:485-518.
7. Thompson MD, Beard DA. 2011. Development of appropriate equations for physiologically-based pharmacokinetic modeling of permeability-limited and flow-limited transport. J Pharmacokinet Pharmacodyn 38:405-421.
8. Dixit R, Riviere J, Krishnan K, Andersen ME. 2003. Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment. J Toxicol Environ Health B Crit Rev 6:1-40.
9. Poulin P, Theil FP. 2000. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
10. Jeffrey P, Summerfield SG. 2007. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37:1135-1151.
11. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
12. EPI Suite. 2008. US Environmental Protection Agency.
13. Blakey GE, Nestorov IA, Arundel PA, Aarons LJ, Rowland M. 1997. Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 25:277-312.
14. Kato Y, Hirate J, Sakaguchi K, Ueno M, Horikoshi I. 1987. Age-dependent changes in phenytoin tissue distribution in rats. J Pharmacobiodyn 10:166-172.
15. Singh P, Roberts MS. 1993. Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application. J Pharmacokinet Biopharm 21:337-373.
16. Higuchi S, Urano C, Kawamura S. 1985. Determination of plasma protein binding of propafenone in rats, dogs and humans by highly sensitive gas chromatography-mass spectrometry. J Chromatogr 341:305-311.
17. Evans GH, Nies AS, Shand DG. 1973. Disposition of propranolol.3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 186:114-122.
18. Dickinson RG, Harland RC, Ilias AM, Rodgers RM, Kaufman SN, Lynn RK, Gerber N. 1979. Disposition of valproic acid in the rat - dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp Ther 211:583-595.
19. Montay G, Goueffon Y, Roquet F. 1984. Absorption, distribution, metabolic-fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother 25:463-472.
20. Kawahara M, Nanbo T, Tsuji A. 1998. Physiologically based pharmacokinetic prediction of p-phenylbenzoic acid disposition in the pregnant rat. Biopharm Drug Dispos 19:445-453.
21. Jusko WJ, Gretch M. 1976. Plasma and tissue protein-binding of drugs in pharmacokinetics. Drug Metab Rev 5:43-140.
22. Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Tsunoo M. 1998. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 26:240-245.
23. Poulin P, Theil FP. 2009. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98:4941-4961.
24. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
25. Scheuplein RJ, Blank IH. 1971. Permeability of the skin. Physiol Rev 51:702-747.
26. Everett NB, Simmons B, Lasher EP. 1956. Distribution of blood (Fe 59) and plasma (I 131) volumes of rats determined by liquid nitrogen freezing. Circ Res 4:419-424.
27. Gallo JM, In Transport processes in pharmaceutical systems (Eds. GL Amidon, PI Lee, EM Topp), Marcel Dekker, Inc.: New York, NY, 2000, pp 55-86.
28. Csajka C, Verotta D. 2006. Pharmacokinetic-pharmacodynamic modelling: History and perspectives. J Pharmacokinet Pharmacodyn 33:227-279.
29. Teorell T. 1937. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Archives Internationales de Pharmacodynamie et de Therapie 57:205-225.
30. Teorell T. 1937. Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration. Archives Internationales de Pharmacodynamie et de Therapie 57:226-240.
31. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. 1971. Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133.
32. Ramsey JC, Andersen ME. 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol 73:159-175.
33. Bischoff KB. 1986. Physiological pharmacokinetics. Bull Math Biol 48:309-322.
34. Espie P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. 2009. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391-407.
35. Khor SP, Mayersohn M. 1991. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood.1. Theoretical considerations. Drug Metab Dispos 19:478-485.
36. Khor SP, Bozigian H, Mayersohn M. 1991. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood.2. Distribution of phencyclidine in the rat. Drug Metab Dispos 19:486-490.
37. Friden M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M. 2010. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 30:150-161.
38. Junot C, Nicolet L, Ezan E, Gonzales MF, Menard J, Azizi M. 1999. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats. J Pharmacol Exp Ther 291:982-987.
39. Giudicelli C, Dricot E, Moati F, Strolin-Benedetti M, Giudicelli JF. 2004. Is it important to correct apparent drug tissue concentrations for blood contamination in the dog? Fundam Clin Pharmacol 18:281-286.
40. Gueorguieva II, Nestorov IA, Rowland M. 2004. Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam. J Pharmacokinet Pharmacodyn 31:185-213.
41. Gallo JM, Lam FC, Perrier DG. 1987. Area method for the estimation of partition-coefficients for physiological pharmacokinetic models. J Pharmacokinet Biopharm 15:271-280.